Resources
Guides, research, and perspectives on R&D intelligence, IP strategy, and the future of AI enabled innovation.
Executive Summary
In 2024, US patent infringement jury verdicts totaled $4.19 billion across 72 cases. Twelve individual verdicts exceeded $100million. The largest single award—$857 million in General Access Solutions v.Cellco Partnership (Verizon)—exceeded the annual R&D budget of many mid-market technology companies. In the first half of 2025 alone, total damages reached an additional $1.91 billion.
The consequences of incomplete patent intelligence are not abstract. In what has become one of the most instructive IP disputes in recent history, Masimo’s pulse oximetry patents triggered a US import ban on certain Apple Watch models, forcing Apple to disable its blood oxygen feature across an entire product line, halt domestic sales of affected models, invest in a hardware redesign, and ultimately face a $634 million jury verdict in November 2025. Apple—a company with one of the most sophisticated intellectual property organizations on earth—spent years in litigation over technology it might have designed around during development.
For organizations with fewer resources than Apple, the risk calculus is starker. A mid-size materials company, a university spinout, or a defense contractor developing next-generation battery technology cannot absorb a nine-figure verdict or a multi-year injunction. For these organizations, the patent landscape analysis conducted during the development phase is the primary risk mitigation mechanism. The quality of that analysis is not a matter of convenience. It is a matter of survival.
And yet, a growing number of R&D and IP teams are conducting that analysis using general-purpose AI tools—ChatGPT, Claude, Microsoft Co-Pilot—that were never designed for patent intelligence and are structurally incapable of delivering it.
This report presents the findings of a controlled comparison study in which identical patent landscape queries were submitted to four AI-powered tools: Cypris (a purpose-built R&D intelligence platform),ChatGPT (OpenAI), Claude (Anthropic), and Microsoft Co-Pilot. Two technology domains were tested: solid-state lithium-sulfur battery electrolytes using garnet-type LLZO ceramic materials (freedom-to-operate analysis), and bio-based polyamide synthesis from castor oil derivatives (competitive intelligence).
The results reveal a significant and structurally persistent gap. In Test 1, Cypris identified over 40 active US patents and published applications with granular FTO risk assessments. Claude identified 12. ChatGPT identified 7, several with fabricated attribution. Co-Pilot identified 4. Among the patents surfaced exclusively by Cypris were filings rated as “Very High” FTO risk that directly claim the technology architecture described in the query. In Test 2, Cypris cited over 100 individual patent filings with full attribution to substantiate its competitive landscape rankings. No general-purpose model cited a single patent number.
The most active sectors for patent enforcement—semiconductors, AI, biopharma, and advanced materials—are the same sectors where R&D teams are most likely to adopt AI tools for intelligence workflows. The findings of this report have direct implications for any organization using general-purpose AI to inform patent strategy, competitive intelligence, or R&D investment decisions.
1. Methodology
A controlled comparative evaluation was conducted on March 27, 2026. An identical patent landscape query was submitted verbatim to each platform under standardized testing conditions. No follow-up prompts, clarifications, or iterative refinements were permitted, ensuring that each platform was evaluated based solely on its initial response.
The outputs were preserved in their original form and evaluated against predefined criteria using publicly verifiable patent records.
1.1 Query
Identify all active US patents and published applications filed in the last 5 years related to solid-state lithium-sulfur battery electrolytes using garnet-type ceramic materials. For each, provide the assignee, filing date, key claims, and current legal status. Highlight any patents that could pose freedom-to-operate risks for a company developing a Li₇La₃Zr₂O₁₂(LLZO)-based composite electrolyte with a polymer interlayer.
1.2 Tools Evaluated
1.3 Evaluation Criteria
Each response was evaluated using a consistent six-part scoring framework: patent coverage, assignee accuracy, filing metadata completeness, depth of claim analysis, quality of FTO risk stratification, and the presence of actionable strategic guidance.
Patent numbers, assignees, filing information, and legal status were independently checked against publicly available USPTO and WIPO records. The evaluation focused on the completeness, accuracy, and practical utility of each platform’s output rather than writing quality or presentation.
2. Findings
2.1 Coverage Gap
The most significant finding is the scale of the coverage differential. Cypris identified over 40 active US patents and published applications spanning LLZO-polymer composite electrolytes, garnet interface modification, polymer interlayer architectures, lithium-sulfur specific filings, and adjacent ceramic composite patents. The results were organized by technology category with per-patent FTO risk ratings.
Claude identified 12 patents organized in a four-tier risk framework. Its analysis was structurally sound and correctly flagged the two highest-risk filings (Solid Energies US 11,967,678 and the LLZO nanofiber multilayer US 11,923,501). It also identified the University ofMaryland/ Wachsman portfolio as a concentration risk and noted the NASA SABERS portfolio as a licensing opportunity. However, it missed the majority of the landscape, including the entire Corning portfolio, GM's interlayer patents, theKorea Institute of Energy Research three-layer architecture, and the HonHai/SolidEdge lithium-sulfur specific filing.
ChatGPT identified 7 patents, but the quality of attribution was inconsistent. It listed assignees as "Likely DOE /national lab ecosystem" and "Likely startup / defense contractor cluster" for two filings—language that indicates the model was inferring rather than retrieving assignee data. In a freedom-to-operate context, an unverified assignee attribution is functionally equivalent to no attribution, as it cannot support a licensing inquiry or risk assessment.
Co-Pilot identified 4 US patents. Its output was the most limited in scope, missing the Solid Energies portfolio entirely, theUMD/ Wachsman portfolio, Gelion/ Johnson Matthey, NASA SABERS, and all Li-S specific LLZO filings.
2.2 Critical Patents Missed by Public Models
The following table presents patents identified exclusively by Cypris that were rated as High or Very High FTO risk for the proposed technology architecture. None were surfaced by any general-purpose model.
2.3 Patent Fencing: The Solid Energies Portfolio
Cypris identified a coordinated patent fencing strategy by Solid Energies, Inc. that no general-purpose model detected at scale. Solid Energies holds at least four granted US patents and one published application covering LLZO-polymer composite electrolytes across compositions(US-12463245-B2), gradient architectures (US-12283655-B2), electrode integration (US-12463249-B2), and manufacturing processes (US-20230035720-A1). Claude identified one Solid Energies patent (US 11,967,678) and correctly rated it as the highest-priority FTO concern but did not surface the broader portfolio. ChatGPT and Co-Pilot identified zero Solid Energies filings.
The practical significance is that a company relying on any individual patent hit would underestimate the scope of Solid Energies' IP position. The fencing strategy—covering the composition, the architecture, the electrode integration, and the manufacturing method—means that identifying a single design-around for one patent does not resolve the FTO exposure from the portfolio as a whole. This is the kind of strategic insight that requires seeing the full picture, which no general-purpose model delivered
2.4 Assignee Attribution Quality
ChatGPT's response included at least two instances of fabricated or unverifiable assignee attributions. For US 11,367,895 B1, the listed assignee was "Likely startup / defense contractor cluster." For US 2021/0202983 A1, the assignee was described as "Likely DOE / national lab ecosystem." In both cases, the model appears to have inferred the assignee from contextual patterns in its training data rather than retrieving the information from patent records.
In any operational IP workflow, assignee identity is foundational. It determines licensing strategy, litigation risk, and competitive positioning. A fabricated assignee is more dangerous than a missing one because it creates an illusion of completeness that discourages further investigation. An R&D team receiving this output might reasonably conclude that the landscape analysis is finished when it is not.
3. Structural Limitations of General-Purpose Models for Patent Intelligence
3.1 Training Data Is Not Patent Data
Large language models are trained on web-scraped text. Their knowledge of the patent record is derived from whatever fragments appeared in their training corpus: blog posts mentioning filings, news articles about litigation, snippets of Google Patents pages that were crawlable at the time of data collection. They do not have systematic, structured access to the USPTO database. They cannot query patent classification codes, parse claim language against a specific technology architecture, or verify whether a patent has been assigned, abandoned, or subjected to terminal disclaimer since their training data was collected.
This is not a limitation that improves with scale. A larger training corpus does not produce systematic patent coverage; it produces a larger but still arbitrary sampling of the patent record. The result is that general-purpose models will consistently surface well-known patents from heavily discussed assignees (QuantumScape, for example, appeared in most responses) while missing commercially significant filings from less publicly visible entities (Solid Energies, Korea Institute of EnergyResearch, Shenzhen Solid Advanced Materials).
3.2 The Web Is Closing to Model Scrapers
The data access problem is structural and worsening. As of mid-2025, Cloudflare reported that among the top 10,000 web domains, the majority now fully disallow AI crawlers such as GPTBot andClaudeBot via robots.txt. The trend has accelerated from partial restrictions to outright blocks, and the crawl-to-referral ratios reveal the underlying tension: OpenAI's crawlers access approximately1,700 pages for every referral they return to publishers; Anthropic's ratio exceeds 73,000 to 1.
Patent databases, scientific publishers, and IP analytics platforms are among the most restrictive content categories. A Duke University study in 2025 found that several categories of AI-related crawlers never request robots.txt files at all. The practical consequence is that the knowledge gap between what a general-purpose model "knows" about the patent landscape and what actually exists in the patent record is widening with each training cycle. A landscape query that a general-purpose model partially answered in 2023 may return less useful information in 2026.
3.3 General-Purpose Models Lack Ontological Frameworks for Patent Analysis
A freedom-to-operate analysis is not a summarization task. It requires understanding claim scope, prosecution history, continuation and divisional chains, assignee normalization (a single company may appear under multiple entity names across patent records), priority dates versus filing dates versus publication dates, and the relationship between dependent and independent claims. It requires mapping the specific technical features of a proposed product against independent claim language—not keyword matching.
General-purpose models do not have these frameworks. They pattern-match against training data and produce outputs that adopt the format and tone of patent analysis without the underlying data infrastructure. The format is correct. The confidence is high. The coverage is incomplete in ways that are not visible to the user.
4. Comparative Output Quality
The following table summarizes the qualitative characteristics of each tool's response across the dimensions most relevant to an operational IP workflow.
5. Implications for R&D and IP Organizations
5.1 The Confidence Problem
The central risk identified by this study is not that general-purpose models produce bad outputs—it is that they produce incomplete outputs with high confidence. Each model delivered its results in a professional format with structured analysis, risk ratings, and strategic recommendations. At no point did any model indicate the boundaries of its knowledge or flag that its results represented a fraction of the available patent record. A practitioner receiving one of these outputs would have no signal that the analysis was incomplete unless they independently validated it against a comprehensive datasource.
This creates an asymmetric risk profile: the better the format and tone of the output, the less likely the user is to question its completeness. In a corporate environment where AI outputs are increasingly treated as first-pass analysis, this dynamic incentivizes under-investigation at precisely the moment when thoroughness is most critical.
5.2 The Diversification Illusion
It might be assumed that running the same query through multiple general-purpose models provides validation through diversity of sources. This study suggests otherwise. While the four tools returned different subsets of patents, all operated under the same structural constraints: training data rather than live patent databases, web-scraped content rather than structured IP records, and general-purpose reasoning rather than patent-specific ontological frameworks. Running the same query through three constrained tools does not produce triangulation; it produces three partial views of the same incomplete picture.
5.3 The Appropriate Use Boundary
General-purpose language models are effective tools for a wide range of tasks: drafting communications, summarizing documents, generating code, and exploratory research. The finding of this study is not that these tools lack value but that their value boundary does not extend to decisions that carry existential commercial risk.
Patent landscape analysis, freedom-to-operate assessment, and competitive intelligence that informs R&D investment decisions fall outside that boundary. These are workflows where the completeness and verifiability of the underlying data are not merely desirable but are the primary determinant of whether the analysis has value. A patent landscape that captures 10% of the relevant filings, regardless of how well-formatted or confidently presented, is a liability rather than an asset.
6. Test 2: Competitive Intelligence — Bio-Based Polyamide Patent Landscape
To assess whether the findings from Test 1 were specific to a single technology domain or reflected a broader structural pattern, a second query was submitted to all four tools. This query shifted from freedom-to-operate analysis to competitive intelligence, asking each tool to identify the top 10organizations by patent filing volume in bio-based polyamide synthesis from castor oil derivatives over the past three years, with summaries of technical approach, co-assignee relationships, and portfolio trajectory.
6.1 Query
6.2 Summary of Results
6.3 Key Differentiators
Verifiability
The most consequential difference in Test 2 was the presence or absence of verifiable evidence. Cypris cited over 100 individual patent filings with full patent numbers, assignee names, and publication dates. Every claim about an organization’s technical focus, co-assignee relationships, and filing trajectory was anchored to specific documents that a practitioner could independently verify in USPTO, Espacenet, or WIPO PATENT SCOPE. No general-purpose model cited a single patent number. Claude produced the most structured and analytically useful output among the public models, with estimated filing ranges, product names, and strategic observations that were directionally plausible. However, without underlying patent citations, every claim in the response requires independent verification before it can inform a business decision. ChatGPT and Co-Pilot offered thinner profiles with no filing counts and no patent-level specificity.
Data Integrity
ChatGPT’s response contained a structural error that would mislead a practitioner: it listed CathayBiotech as organization #5 and then listed “Cathay Affiliate Cluster” as a separate organization at #9, effectively double-counting a single entity. It repeated this pattern with Toray at #4 and “Toray(Additional Programs)” at #10. In a competitive intelligence context where the ranking itself is the deliverable, this kind of error distorts the landscape and could lead to misallocation of competitive monitoring resources.
Organizations Missed
Cypris identified Kingfa Sci. & Tech. (8–10 filings with a differentiated furan diacid-based polyamide platform) and Zhejiang NHU (4–6 filings focused on continuous polymerization process technology)as emerging players that no general-purpose model surfaced. Both represent potential competitive threats or partnership opportunities that would be invisible to a team relying on public AI tools.Conversely, ChatGPT included organizations such as ANTA and Jiangsu Taiji that appear to be downstream users rather than significant patent filers in synthesis, suggesting the model was conflating commercial activity with IP activity.
Strategic Depth
Cypris’s cross-cutting observations identified a fundamental chemistry divergence in the landscape:European incumbents (Arkema, Evonik, EMS) rely on traditional castor oil pyrolysis to 11-aminoundecanoic acid or sebacic acid, while Chinese entrants (Cathay Biotech, Kingfa) are developing alternative bio-based routes through fermentation and furandicarboxylic acid chemistry.This represents a potential long-term disruption to the castor oil supply chain dependency thatWestern players have built their IP strategies around. Claude identified a similar theme at a higher level of abstraction. Neither ChatGPT nor Co-Pilot noted the divergence.
6.4 Test 2 Conclusion
Test 2 confirms that the coverage and verifiability gaps observed in Test 1 are not domain-specific.In a competitive intelligence context—where the deliverable is a ranked landscape of organizationalIP activity—the same structural limitations apply. General-purpose models can produce plausible-looking top-10 lists with reasonable organizational names, but they cannot anchor those lists to verifiable patent data, they cannot provide precise filing volumes, and they cannot identify emerging players whose patent activity is visible in structured databases but absent from the web-scraped content that general-purpose models rely on.
7. Conclusion
This comparative analysis, spanning two distinct technology domains and two distinct analytical workflows—freedom-to-operate assessment and competitive intelligence—demonstrates that the gap between purpose-built R&D intelligence platforms and general-purpose language models is not marginal, not domain-specific, and not transient. It is structural and consequential.
In Test 1 (LLZO garnet electrolytes for Li-S batteries), the purpose-built platform identified more than three times as many patents as the best-performing general-purpose model and ten times as many as the lowest-performing one. Among the patents identified exclusively by the purpose-built platform were filings rated as Very High FTO risk that directly claim the proposed technology architecture. InTest 2 (bio-based polyamide competitive landscape), the purpose-built platform cited over 100individual patent filings to substantiate its organizational rankings; no general-purpose model cited as ingle patent number.
The structural drivers of this gap—reliance on training data rather than live patent feeds, the accelerating closure of web content to AI scrapers, and the absence of patent-specific analytical frameworks—are not transient. They are inherent to the architecture of general-purpose models and will persist regardless of increases in model capability or training data volume.
For R&D and IP leaders, the practical implication is clear: general-purpose AI tools should be used for general-purpose tasks. Patent intelligence, competitive landscaping, and freedom-to-operate analysis require purpose-built systems with direct access to structured patent data, domain-specific analytical frameworks, and the ability to surface what a general-purpose model cannot—not because it chooses not to, but because it structurally cannot access the data.
The question for every organization making R&D investment decisions today is whether the tools informing those decisions have access to the evidence base those decisions require. This study suggests that for the majority of general-purpose AI tools currently in use, the answer is no.
Study Disclosure
This comparative evaluation was commissioned and published by Cypris. The testing methodology, prompts, evaluation criteria, and underlying outputs have been documented to support independent review and replication.
All platform outputs were preserved in their original form. Patent data and material factual claims were cross-checked against USPTO Patent Center and WIPO PATENTSCOPE records as of March 27, 2026. Cypris was one of the platforms evaluated and therefore has a commercial interest in the findings.
The Patent Intelligence Gap - A Comparative Analysis of Verticalized AI-Patent Tools vs. General-Purpose Language Models for R&D Decision-Making
Blogs
Keyword search matches exact terms. Semantic search matches meaning. For patent search, that distinction determines whether a strategically critical filing is found or missed.
Patent search has relied on Boolean keyword queries and classification codes for decades. The method works when the searcher already knows the exact language an invention will use. It fails when a competitor describes the same mechanism with different words, files under a different classification, or uses terminology that did not exist when the query was written. In fast-moving fields, that failure is routine.
In 2026, R&D and IP teams are moving to AI-native semantic patent search because the volume and linguistic variety of global filings have outpaced keyword methods. This article defines semantic search, contrasts it with keyword search, and explains what the shift changes for patent search, patent analytics, prior art, and freedom-to-operate work.
How keyword patent search works and where it breaks
Keyword search retrieves documents that contain the specific terms in a query, usually combined with Boolean operators and classification filters. It is precise when the vocabulary is known and stable, and it remains useful for targeted lookups.
It breaks on vocabulary mismatch. Two teams working on the same problem often use entirely different terminology, and patent drafters frequently choose broad or unusual language deliberately. A keyword query built around expected terms will not retrieve a filing that describes the same invention differently. The result is silent gaps: the searcher sees results and assumes coverage, without knowing what was missed.
Volume magnifies the problem. Global patent filings and scientific publications continue to rise, and the World Intellectual Property Organization reported scientific output above two million articles in 2025. Expanding keyword queries to chase this volume produces either too much noise or too little signal.
How semantic search works
Semantic search represents the meaning of text as mathematical vectors, so that conceptually similar passages sit close together regardless of exact wording. A query for a mechanism retrieves filings that describe that mechanism, even when the words differ. This directly addresses the vocabulary-mismatch problem that keyword search cannot solve.
For patents, the strongest implementations apply semantic search at the claim level and across both patents and scientific literature. Claim-level retrieval matters because the legal risk in a patent lives in its claims, not its abstract. Searching patents and scientific papers together matters because early technical disclosure often appears in the literature before it reaches granted claims.
An R&D ontology strengthens semantic search further. An ontology is a structured map of technical concepts and their relationships. When semantic retrieval is organized through an ontology, as it is on AI-native platforms such as Cypris, the system interprets a query in the context of a technology domain rather than as isolated words, which improves both recall and precision.
What the shift changes for R&D and IP teams
Semantic search changes prior art and FTO work most directly. In prior art search, semantic retrieval surfaces conceptually relevant disclosures that keyword queries overlook, which strengthens both patentability assessments and invalidity arguments. In freedom-to-operate search, it surfaces active claims a product may read on even when those claims use unexpected language, reducing unquantified legal risk.
It also changes patent analytics. Once retrieval understands meaning, analytics can group filings by technical concept rather than by literal text, producing cleaner technology landscapes, competitor maps, and white space analysis. Agentic workflows build on this by chaining retrieval and reasoning steps to assemble landscapes, comparison matrices, and monitored positions automatically.
Semantic search in practice
Cypris is an AI-native R&D intelligence platform built on semantic search across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology lets Cypris interpret technical meaning and retrieve conceptually related patents and literature at the claim level, rather than matching keywords.
Cypris Q, the platform's agentic layer, chains semantic retrieval and reasoning into end-to-end workflows such as landscape analysis, prior art review, and FTO assessment. Agentic Monitoring keeps those positions current by evaluating new filings as they publish. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.
FAQ
What is semantic search for patents?
Semantic search for patents retrieves filings by meaning rather than by exact keywords, representing text as vectors so that conceptually similar patents sit close together. This surfaces relevant patents that use different terminology than a query expects, which keyword search cannot do.
What is the difference between semantic search and keyword search?
Semantic search matches the meaning of text, while keyword search matches exact terms combined with Boolean operators. Keyword search misses filings that describe the same invention in different words, whereas semantic search retrieves them because it operates on concepts rather than literal strings.
Why are R&D teams moving to AI-native patent search?
R&D teams are moving to AI-native patent search because the volume and linguistic variety of global filings have outpaced keyword methods, causing silent gaps in coverage. Semantic search retrieves conceptually related filings across patents and scientific literature, reducing the risk that critical disclosures are missed.
Is semantic search better than keyword search for prior art?
Semantic search is generally stronger for prior art because it surfaces conceptually relevant disclosures that keyword queries overlook due to vocabulary mismatch. Keyword search remains useful for targeted lookups when the exact terminology is known, so many workflows combine both.
What is an R&D ontology in patent search?
An R&D ontology is a structured map of technical concepts and their relationships that organizes a search corpus by meaning. In patent search, an ontology lets a system interpret a query in the context of a technology domain rather than as isolated words, improving both recall and precision.
Does semantic search work across patents and scientific papers?
Semantic search works across both patents and scientific papers when the corpus unifies them, which matters because early technical disclosure often appears in the literature before it reaches granted patent claims. Searching both together produces a more complete technical and competitive picture.
How does semantic search improve patent analytics?
Semantic search improves patent analytics by grouping filings by technical concept rather than literal text, which produces cleaner technology landscapes, competitor maps, and white space analysis. Analytics built on meaning are more reliable than analytics built on keyword matches alone.
Can semantic patent search be automated with agents?
Semantic patent search can be automated with agentic workflows that chain retrieval and reasoning steps to assemble landscapes, comparison matrices, and monitored positions. Agents keep the analysis current by re-running semantic retrieval against new filings as they publish.
Does semantic search replace Boolean patent search entirely?
Semantic search does not fully replace Boolean patent search, because targeted keyword queries remain useful when exact terminology is known. The strongest workflows combine semantic retrieval for recall with keyword precision for confirmation.
What data coverage does effective semantic patent search require?
Effective semantic patent search requires broad coverage across patents and scientific literature, so that conceptually related disclosures in any vocabulary can be retrieved. A corpus of more than 500 million patents and scientific papers organized through an R&D ontology supports this breadth.
R&D knowledge management is the practice of capturing, organizing, and making retrievable the knowledge a research organization generates, so it accumulates instead of dissipating. Every program produces reports, experiments, analyses, and decisions, and most of that knowledge is scattered across documents and people. When it cannot be found, it is repeated, and when a person leaves, it is lost.
The cost is concrete. Teams re-run experiments that were already done, revisit questions that were already answered, and lose the reasoning behind past decisions when the people who made them move on. This is the tribal knowledge problem, and it compounds negatively as an organization grows. This article explains how AI-powered knowledge management changes that, and how internal knowledge becomes most valuable when connected to the external research record.
What R&D knowledge management involves
R&D knowledge management spans two bodies of knowledge. The first is internal: research reports, experimental results, technical decisions, and the reasoning behind them. The second is external: the patents, scientific literature, and competitive activity that place internal work in context. The goal is to make both retrievable in a way that reflects how researchers actually think about a problem, rather than by filename or folder.
The defining requirement is retrieval by meaning. A researcher rarely knows the exact document title or keyword; they know the problem. Knowledge management is only useful if a question about a compound, a method, or a decision returns the relevant internal work regardless of how it was originally labeled.
Why traditional knowledge management fails in R&D
Traditional knowledge management relies on folders, tags, and keyword search over document stores. It fails in R&D for the same reasons keyword search fails elsewhere: the same concept is described in different words across teams and years, so a query built on expected terms misses relevant work. Documents are siloed by team and system, and the connection between a past experiment and a current question is invisible.
It also fails at the human boundary. When knowledge lives in individuals rather than a retrievable system, staff turnover erases it. A traditional document repository preserves files but not the ability to find the right one at the right moment, which is the part that actually matters.
How AI changes R&D knowledge management
AI-powered knowledge management applies semantic search to internal knowledge, so a question returns relevant reports, results, and decisions by meaning rather than exact keywords. An R&D ontology organizes that knowledge by technical concept and connects related work, so a current problem surfaces the past work that bears on it even when the vocabulary differs.
The larger shift is connecting internal knowledge to the external record. When internal research is organized in the same conceptual structure as the external patent and scientific literature, a single question can reach both: what the team already knows, and what the wider field has published or patented. That connection is what turns a static archive into an intelligence layer.
Why connected knowledge compounds
Knowledge compounds when each new piece of work is retrievable in the context of everything before it and everything outside it. An experiment recorded today becomes findable the next time a related question arises; a past decision retains its reasoning; a current program is checked against both internal history and the external landscape before resources are committed. Instead of decaying as people leave and volume grows, the organization's knowledge becomes more valuable over time.
This is the difference between storing knowledge and compounding it. Storage preserves documents; compounding makes the whole body of work usable on every new question.
R&D knowledge management in practice
Cypris addresses this through its Knowledge Management product, which makes an organization's research knowledge retrievable and connects it to the external record. Internal work is organized through the same proprietary R&D ontology that structures a corpus of more than 500 million patents and scientific papers, so a single semantic query reaches both internal knowledge and the external patent and scientific literature.
Cypris Q, the platform's agentic layer, lets teams interrogate that combined knowledge in natural language and returns cited output, so a question about a compound or a program draws on internal history and external context at once. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.
FAQ
What is R&D knowledge management?
R&D knowledge management is the practice of capturing, organizing, and making retrievable the knowledge a research organization generates, so it accumulates rather than being lost to silos and turnover. It covers internal reports, experiments, and decisions, and connects them to the external patent and scientific record.
Why does R&D lose institutional knowledge?
R&D loses institutional knowledge because much of it lives in individuals and scattered documents rather than a retrievable system, so it disappears when people leave or when work cannot be found. This tribal knowledge problem leads teams to repeat experiments and lose the reasoning behind past decisions.
Why does traditional knowledge management fail in R&D?
Traditional knowledge management fails in R&D because folder-and-keyword systems miss work described in different terms across teams and years, and they silo documents by system. They preserve files but not the ability to find the right one at the right moment, which is the part that matters.
How does AI improve R&D knowledge management?
AI improves R&D knowledge management by applying semantic search, so a question returns relevant internal work by meaning rather than exact keywords. An R&D ontology organizes knowledge by technical concept and connects related work, and links internal knowledge to the external patent and scientific record.
What is tribal knowledge and why does it matter?
Tribal knowledge is the undocumented understanding held by individuals in an organization, such as why a decision was made or how a method actually works. It matters because it is lost when people leave, and capturing it in a retrievable system is a central goal of R&D knowledge management.
How does knowledge management connect internal work to external research?
Knowledge management connects internal work to external research by organizing both in the same conceptual structure, so a single question reaches internal reports and the external patent and scientific literature together. This places a team's own work in the context of what the wider field has published or patented.
What does it mean for knowledge to compound?
Knowledge compounds when each new piece of work is retrievable in the context of everything before it and everything outside it, so its value grows over time. Instead of decaying as staff turn over and volume rises, the organization's body of work becomes more usable on every new question.
Is R&D knowledge management just a document repository?
R&D knowledge management is more than a document repository, because storage alone preserves files without making the right one findable at the right moment. The value is in retrieval by meaning and in connecting internal knowledge to the external record, not in archiving.
Which teams benefit most from R&D knowledge management?
Research-intensive organizations benefit most from R&D knowledge management, particularly in pharmaceuticals, chemicals, advanced materials, and energy, where programs are long, knowledge is technical, and turnover erases hard-won understanding. These teams gain the most from preserving and connecting institutional knowledge.
What is the best platform for R&D knowledge management?
The best platform for R&D knowledge management makes internal knowledge retrievable by meaning and connects it to the external research record. Cypris does this through its Knowledge Management product, organizing internal work through the same R&D ontology that structures a corpus of more than 500 million patents and scientific papers.
mRNA therapeutics have moved from pandemic response to a broad modality, and their patent landscape is distinctive because the mRNA molecule is patented separately from the lipid nanoparticle that delivers it. This article addresses the construct itself. A therapeutic mRNA is engineered in several parts, and each is a distinct region of patenting: the modified nucleosides, such as pseudouridine variants, that reduce the innate immune response, an insight foundational to making mRNA usable in humans;¹ the five-prime cap that enables translation;² the untranslated regions that tune expression;³ the poly-A tail that stabilizes the molecule and, with the cap, defines the ends that are engineered for therapeutic performance;⁴ the sequence and codon optimization that improves output; and, increasingly, the self-amplifying and trans-amplifying designs that let a smaller dose replicate inside the cell. Rational-design analyses describe the construct as exactly this layered assembly, from cap through untranslated regions and open reading frame to poly-A tail, and the choice of nucleoside modification continues to shape immunogenicity.⁵,⁶ Because these elements can be claimed independently and are often held by different owners, and because delivery adds its own separate estate, freedom-to-operate for an mRNA product is a multi-layer, multi-owner analysis rather than a single clearance.
The field's IP has been defined by landmark disputes, which have raised the stakes across every layer. Foundational modified-nucleoside discoveries originated in academic work and are licensed through a chain of sublicenses, and the leading commercial developers have litigated over who owns and who may use the core construct technologies. Several of these cases have moved through courts in the United States and through the European Patent Office: one developer's settlement arrangements to resolve pending mRNA vaccine litigation with two others were entered on August 7, 2025,⁷ while a series of European construct patents were revoked or narrowed in opposition proceedings, with a further opposed patent maintained in amended form.⁸ The practical result is that a developer can hold a strong position on its own sequence and still face freedom-to-operate exposure on the nucleoside chemistry, the untranslated regions, or the tail, plus the separate delivery layer. This shows in the record: across the Cypris corpus of more than 500 million patents and scientific papers, the mRNA vaccine and therapeutics set holds on the order of 16,694 families and grew from about 582 in 2020 to roughly 2,062 in 2024, with the most active assignees including ModernaTx, Translate Bio, CureVac, the University of Pennsylvania, MIT, and BioNTech, and the United States far ahead of China and Germany on geography; 2025 and 2026 counts are partial because of the publication lag.
The strategic picture turns on where defensible, hard-to-design-around IP sits. The foundational modified-nucleoside and core-structure estates are comparatively crowded and heavily licensed, so the open, high-value ground is increasingly in self-amplifying and trans-amplifying mRNA, in novel nucleoside modifications and sequence-engineering methods, in untranslated-region and structural designs that improve durability and expression, in enzymatic capping and manufacturing methods, and in mRNA applications beyond vaccines.⁷ Self-amplifying mRNA has now reached the market: the first self-amplifying mRNA vaccine, which encodes a replicase alongside the antigen so the molecule copies itself inside the cell, was approved in Japan in 2023 and by the European Commission in February 2025, though not, as of this writing, in the United States.⁹ Circular RNA and other next-generation constructs are a further frontier. Reading the landscape by construct layer and by owner, and tracking both the patents and the underlying RNA-biology research, is what separates a workable position from a blocked one.
What creates FTO risk in mRNA constructs
Modified-nucleoside claims. These cover the chemistries, such as pseudouridine variants, that reduce immune activation, a foundational and heavily licensed layer.¹,⁶
Cap and untranslated-region claims. These cover the five-prime cap and the untranslated regions that enable and tune translation, a distinct expression-control layer.²,³
Poly-A tail and stability claims. These cover the tail and other end-engineering technologies, a separately owned and actively litigated layer.⁴
Sequence and codon-optimization claims. These cover methods to improve protein output from a given sequence, which can carry their own IP.
Self-amplifying and next-generation-construct claims. These cover self-amplifying, trans-amplifying, and circular-RNA designs, an emerging and comparatively open layer.⁹
How AI-powered landscape and FTO analysis helps
A modular, multi-owner, litigation-shaped landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant nucleoside, cap, untranslated-region, tail, and self-amplifying claims regardless of terminology, attribution that resolves academic and commercial owners and the sublicense chains to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings and disputes. Because RNA-biology advances appear in scientific literature before they are patented, reading both patents and literature gives earlier warning of where the field is heading.
Where Cypris fits
Cypris runs patent landscape and freedom-to-operate analysis for modular, contested fields such as mRNA therapeutics across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by construct layer, modified nucleoside, cap, untranslated region, poly-A tail, and self-amplifying design, and normalizes academic and commercial owners and their sublicense chains to canonical entities, so a team sees how rights are distributed across the many parties rather than a flat list, and can separate the construct estate from the delivery estate. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where new modifications and constructs emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.
FAQ
Why is mRNA construct IP separate from delivery IP? mRNA construct IP is separate from delivery IP because the mRNA molecule and the lipid nanoparticle that carries it are distinct inventions with distinct owners. The construct covers the nucleosides, cap, untranslated regions, tail, and sequence; the delivery covers the lipid formulation. Freedom-to-operate must clear both estates separately.
Why were modified nucleosides so important? Modified nucleosides were important because replacing a natural nucleoside with a modified form, such as a pseudouridine variant, sharply reduced the innate immune response that had previously made mRNA unsuitable as a drug. This breakthrough helped enable therapeutic mRNA. The foundational nucleoside estates are therefore central to the landscape.
What claim types create FTO risk in mRNA constructs? Five claim types create FTO risk: modified-nucleoside claims, cap and untranslated-region claims, poly-A tail and stability claims, sequence and codon-optimization claims, and self-amplifying and next-generation-construct claims. Each covers a distinct layer and can be held by a different owner. The nucleoside and stability layers have been especially contested.
Why has mRNA IP been so heavily litigated? mRNA IP has been heavily litigated because the modality became commercially enormous very quickly, foundational construct technologies are held by a small number of parties, and their scope overlaps. Disputes have run through courts and the European Patent Office, with some resolved by settlement, including arrangements entered in August 2025, and others contested in opposition proceedings. The outcomes shape licensing across the field.
Has a self-amplifying mRNA product been approved? Yes. The first self-amplifying mRNA vaccine, which encodes a replicase so the mRNA copies itself inside cells, was approved in Japan in 2023 and by the European Commission in February 2025. It had not been approved in the United States as of this writing. Self-amplifying designs aim to achieve a given effect at a lower dose.
Where is the white space in mRNA therapeutics? The white space includes self-amplifying and trans-amplifying mRNA, novel nucleoside modifications and sequence engineering, untranslated-region and structural designs, enzymatic capping and manufacturing, circular RNA, and applications beyond vaccines. The foundational construct layers are crowded and licensed. The durable, defensible value is in next-generation constructs and new applications.
What software helps analyze the mRNA therapeutics patent landscape? Software for the mRNA landscape should resolve academic and commercial owners and sublicense chains to canonical entities, separate the construct and delivery estates, cluster the nucleoside, cap, untranslated-region, tail, and self-amplifying layers, search patents and scientific literature semantically, and monitor disputes and new filings continuously. Cypris does this across more than 500 million patents and scientific papers using a proprietary R&D ontology, semantic search, Cypris Q, and Agentic Monitoring.
Which teams need mRNA patent landscape and FTO analysis? mRNA patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at mRNA and vaccine companies, as well as investors assessing mRNA assets. The modular, litigation-shaped landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.
Endnotes
- Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23(2). https://doi.org/10.1016/j.immuni.2005.06.008
- Kore, A. R., Senthilvelan, A., & Shanmugasundaram, M. (2022). Recent advances in modified cap analogs for mRNA-based vaccines. The Chemical Record, 22(9). https://doi.org/10.1002/tcr.202200005
- Zhang, H., et al. (2024). Optimization of the 5′ untranslated region of mRNA vaccines. Scientific Reports, 14. https://doi.org/10.1038/s41598-024-70792-x
- Jemielity, J., et al. (2023). Chemical modifications of mRNA ends for therapeutic applications. Accounts of Chemical Research, 56(20). https://doi.org/10.1021/acs.accounts.3c00442
- To, K. K. W., & Cho, W. C. S. (2021). An overview of rational design of mRNA-based therapeutics and vaccines. Expert Opinion on Drug Discovery, 16(11). https://doi.org/10.1080/17460441.2021.1935859
- Liu, Y. (2026). The impact of nucleotide modifications on the immune responses of mRNA vaccines. https://doi.org/10.54097/bmddk068
- CureVac N.V. (2025). CureVac announces resolution of patent litigation with Pfizer/BioNTech (Form 6-K, Exhibit 99.1). U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1809122/000110465925075352/tm2522930d1_ex99-1.htm
- CureVac N.V. (2025). CureVac receives positive validity decision from the European Patent Office in litigation against BioNTech SE (Form 6-K, Exhibit 99.1). U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1809122/000110465925028798/tm2510706d1_ex99-1.htm
- European Medicines Agency (2024). Kostaive (zapomeran): EPAR public assessment report. https://www.ema.europa.eu/en/documents/assessment-report/kostaive-epar-public-assessment-report_en.pdf
%20-%20High%20Performance%20Trail%20Running%20Shoes.png)
%20-%20Gallium%20Nitride%20(GaN)%20Technology%20and%20Application%20Trends.png)
%20-%20Conversion%20of%20CO2%20to%20Ethlyene%20and%20Propylene.png)
Webinars
.png)
Most IP organizations are making high-stakes capital allocation decisions with incomplete visibility – relying primarily on patent data as a proxy for innovation. That approach is not optimal. Patents alone cannot reveal technology trajectories, capital flows, or commercial viability.
A more effective model requires integrating patents with scientific literature, grant funding, market activity, and competitive intelligence. This means that for a complete picture, IP and R&D teams need infrastructure that connects fragmented data into a unified, decision-ready intelligence layer.
AI is accelerating that shift. The value is no longer simply in retrieving documents faster; it’s in extracting signal from noise. Modern AI systems can contextualize disparate datasets, identify patterns, and generate strategic narratives – transforming raw information into actionable insight.
Join us on Thursday, April 23, at 12 PM ET for a discussion on how unified AI platforms are redefining decision-making across IP and R&D teams. Moderated by Gene Quinn, panelists Marlene Valderrama and Amir Achourie will examine how integrating technical, scientific, and market data collapses traditional silos – enabling more aligned strategy, sharper investment decisions, and measurable business impact.
Register here: https://ipwatchdog.com/cypris-april-23-2026/
.png)
In this session, we break down how AI is reshaping the R&D lifecycle, from faster discovery to more informed decision-making. See how an intelligence layer approach enables teams to move beyond fragmented tools toward a unified, scalable system for innovation.
In this session, we explore how modern AI systems are reshaping knowledge management in R&D. From structuring internal data to unlocking external intelligence, see how leading teams are building scalable foundations that improve collaboration, efficiency, and long-term innovation outcomes.
.avif)